Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Chikungunya Virus May Lead to Long-Term Joint Pain

Linda Childers  |  November 18, 2020

For now, Dr. Chang says prevention is key.

“DEET works better than other insect repellants for mosquitoes and can prevent transmission of the CHIKV and Zika viruses,” Dr. Chang says. “Patients traveling to a hot, humid area where infection cases have been reported should be encouraged to use DEET over their sunscreen as a precaution.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Linda Childers is a health writer located in the San Francisco Bay Area.

References

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE
  1. Chang AY, Tritsch SR, Encinales L, et al. Chronic joint pain three years after chikungunya virus infection largely characterized by relapsing-remitting symptoms. J Rheumatol. 2020 Aug 1;47(8):1267–1274. Epub 2019 Jul 1.
  2. Centers for Disease Control & Prevention. Chikungunya virus. 2019 Sep 19.
  3. Chang AY, Encinales L, Pacheco N, et al. Frequency of chronic joint pain following a chikungunya virus infection: A Colombia cohort study. Arthritis Rheumatol. 2018 Apr;70(4):578–584. Epub 2018 Mar 2.
  4. Hackett DW. Chikungunya vaccine candidate to begin testing in Europe. Precision Vaccination. 2020 Jan 14.

Page: 1 2 3 | Single Page
Share: 

Filed under:ConditionsPain Syndromes Tagged with:arthritis painchikungunyaCHIKVChronic painJoint Pain

Related Articles

    Chikungunya: What Every Rheumatologist Needs to Know

    November 2, 2014

    How to spot, diagnose and treat this rapidly spreading mosquito-borne viral illness whose symptoms mimic arthritis

    Mosquito-Borne Chikungunya Virus Can Cause Long-Term Arthritis

    September 20, 2018

    Chikungunya is among a group of 16 diseases transmitted through mosquito, tick or flea bites that is of increasing public health concern in the U.S. Although few rheumatologists are likely to diagnose patients with the acute phase of the disease, they may encounter a handful of patients each year who complain of persistent, and often…

    Chikungunya Virus Vaccine Shows Promise in Early Clinical Trial

    April 21, 2020

    NEW YORK (Reuters Health)—A new chikungunya virus-like-particle vaccine appears to be safe and immunogenic, according to results from a phase 2 trial. “The phase 2 safety, tolerability and immunogenicity were similar to the data seen in an earlier phase 1 study,” Grace L. Chen, MD, of the National Institutes of Health Vaccine Research Center, Bethesda,…

    Experimental Drug Combination Curbs Chikungunya Arthritis in Mice

    May 16, 2017

    Doctors have had few options to treat the chronic rheumatoid arthritis-like symptoms associated with chikungunya virus infections beyond over-the-counter pain relievers. A recent study in Science Translational Medicine has spurred new optimism by finding that a combination therapy—the anti-rheumatic drug abatacept paired with a chikungunya-neutralizing monoclonal antibody—abolished acute symptoms in infected mice.1 The strategy must…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences